柳彤彤, 韩燕星, 蒋建东, 詹芸. 矽肺药物治疗的研究进展J. 药学学报, 2023, 58(5): 1196-1203. DOI: 10.16438/j.0513-4870.2022-1412
引用本文: 柳彤彤, 韩燕星, 蒋建东, 詹芸. 矽肺药物治疗的研究进展J. 药学学报, 2023, 58(5): 1196-1203. DOI: 10.16438/j.0513-4870.2022-1412
LIU Tong-tong, HAN Yan-xing, JIANG Jian-dong, ZHAN Yun. The developments of silicosis drugsJ. Acta Pharmaceutica Sinica, 2023, 58(5): 1196-1203. DOI: 10.16438/j.0513-4870.2022-1412
Citation: LIU Tong-tong, HAN Yan-xing, JIANG Jian-dong, ZHAN Yun. The developments of silicosis drugsJ. Acta Pharmaceutica Sinica, 2023, 58(5): 1196-1203. DOI: 10.16438/j.0513-4870.2022-1412

矽肺药物治疗的研究进展

The developments of silicosis drugs

  • 摘要: 尘肺是我国发病人数最多、最常见的职业病, 严重危害人民身体健康。根据吸入空气污染物的不同, 尘肺分为: 煤肺、矽肺、石棉肺等, 其中矽肺最为常见且最严重。矽肺是由于长期暴露于职业环境中游离二氧化硅(silicon dioxide, SiO2) 含量较高的粉尘引起的以肺组织弥漫性纤维化为主要特点的全身性疾病, 预后较差, 治愈困难。在矽肺发病早期采用及时正确的药物干预对疾病的治疗具有决定性的作用, 但遗憾的是目前缺乏能有效延缓或逆转矽肺纤维化的药物。本综述按照疾病发病机制分类, 总结探讨了可能应用于临床治疗矽肺的药物及部分未成药化合物, 为矽肺临床治疗提供参考。

     

    Abstract: Pneumoconiosis is the most common occupational disease in China, which severely endangers people's health. Depending on the inhaled air pollutants, pneumoconiosis is classified as anthracosis, silicosis, asbestosis, etc., among which silicosis is the most common and serious. Silicosis is a systemic, poor prognostic disease characterized by diffuse fibrosis of lung tissue, which is caused by long-term exposure to dust with high levels of free silicon dioxide (SiO2) in the occupational environment. Appropriate treatment in time is important for the disease. Unfortunately, no effective drugs have been approved to delay or even reverse pulmonary fibrosis caused by SiO2. This review briefly classifies potent therapeutic drugs and compounds in term of mechanisms, providing the probability for clinical treatment of silicosis.

     

/

返回文章
返回